|Bid||31.00 x 800|
|Ask||31.20 x 1000|
|Day's Range||30.81 - 34.30|
|52 Week Range||28.58 - 61.69|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||72.11|
LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three investor conferences as follows: Evercore ISI 4th Annual HEALTHCONx Virtual Conference: fireside chat at 9:40am ET on 1 December 2021. The fireside chat will feature Augustus John Rush MD, Adjunct Professor in the Department of Psychiatry and Beh
Key Takeaways; Cannabis Sector Gage raises $55 million to fuel its marijuana growth in Michigan. Ayr Wellness to acquire two Chicago cannabis stores for at least $55 million. Canada’s High Tide to acquire 80% of Colorado CBD firm NuLeaf Naturals. Germany to legalize recreational cannabis sales, incoming coalition pledges. Key Takeaways; Psychedelic Sector Numinus Receives […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.
Compass Pathways (NASDAQ: CMPS) has released data for a phase 2b study of its COMP360 psilocybin treatment for depression. In this Motley Fool Live video recorded on November 15, Motley Fool contributors Keith Speights and Brian Orelli point out that the therapy helped reduce patients' depression symptoms, but the drug's effectiveness seemed to wane over time and adverse effects were seen in patients taking higher doses.